NASDAQ:SLS SELLAS Life Sciences Group Q3 2025 Earnings Results & Report $8.03 -0.39 (-4.63%) Closing price 04:00 PM EasternExtended Trading$9.62 +1.59 (+19.75%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. SELLAS Life Sciences Group beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.06 versus the -$0.0767 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call4:00 PM ET SELLAS Life Sciences Group EPS ResultsActual EPS-$0.06Consensus EPS -$0.0767Beat/MissBeat by +$0.0167One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersSELLAS Life Sciences Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSELLAS Life Sciences Group's Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) SELLAS Life Sciences Group Q3 2025 Earnings FAQ Did SELLAS Life Sciences Group beat earnings estimates for Q3 2025? SELLAS Life Sciences Group (NASDAQ:SLS) reported earnings of -$0.06 per share for Q3 2025, beating the consensus estimate of -$0.0767. The report was announced on Wednesday, November 12, 2025. When is SELLAS Life Sciences Group's next earnings date? SELLAS Life Sciences Group's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for SELLAS Life Sciences Group on the company's earnings history page. SELLAS Life Sciences Group Earnings HeadlinesSELLAS Life Sciences Group (SLS) Stock Forecast & Price Target2 hours ago | tipranks.comSELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update4 hours ago | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 12 at 1:00 AM | Weiss Ratings (Ad)SELLAS Life Sciences Group (SLS) Expected to Post Quarterly Earnings on WednesdayNovember 11 at 1:41 AM | americanbankingnews.comSLS stock rises after-hours: State Street reveals over 5% stake — and one fund manager boosted holdings by nearly 1,000%November 10 at 10:43 PM | msn.comSELLAS Life Sciences Group (SLS) AI Stock AnalysisNovember 6, 2026 | tipranks.comSee More SELLAS Life Sciences Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email. Email Address About SELLAS Life Sciences GroupSELLAS Life Sciences Group (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer. SELLAS has also been developing SLS009, a small-molecule CDK9 inhibitor being studied for blood cancers, including acute myeloid leukemia. SELLAS is headquartered in New York. Its chief executive officer is Angelos Stergiou, who also serves as the company’s chairman.View SELLAS Life Sciences Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
